{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T06:08:58Z","timestamp":1779170938416,"version":"3.51.4"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Therapeutic cancer vaccines can generate measurable antigen-specific immune responses in humans, yet tumor regression is often incomplete, inconsistent, or short-lived. In immunologically cold tumors, this pattern may reflect not an absolute inability to prime immunity, but difficulty advancing induced immunity through the full sequence required for tumor control. Peripheral blood responses may be real and still be biologically inadequate if they contract early, fail to acquire productive trafficking programs sufficient for tissue entry, lose functional competence under chronic antigen stress, or remain constrained by the suppressive tumor microenvironment. The manuscript advances a sequential, feedback-guided adjuvant framework in which peptide vaccination remains the backbone but is preceded and followed by distinct support phases. A Phase 0 immune-readiness step, potentially using IL-7 (e.g., CYT107), is intended to improve the baseline substrate before antigen exposure. Phase 1 priming uses peptide vaccination on a commonly used adjuvant backbone such as Montanide ISA-51 or poly-ICLC (Hiltonol), while radiation and\/or STING-based strategies are treated as context-dependent enhancers rather than replacements for priming. IL-15-centered consolidation is then used to support expansion and persistence. A formal trafficking assessment follows so that blood-only success is not overinterpreted. IL-21 is positioned later as a persistence- and quality-support cytokine when response quality declines. The framework also addresses why otherwise rational protocols can fail at the chemokine-trafficking step: CXCR3-dependent tumor entry is not interchangeable with generic inflammation, CCR5 biology is context dependent, and IL-12, although biologically attractive and previously tested as a vaccine adjuvant, is best viewed here as an optional, context-specific amplifier rather than a universal backbone. Although organized as sequential phases, the framework is intended as a bottleneck-guided and iterative design logic in which phases may overlap, repeat, or be entered in partial parallel depending on the dominant biologic constraint. The central hypothesis is that vaccine programs that progress beyond priming into trafficking-competent and functionally sustained states are predicted to correlate more closely with disease control than programs judged mainly by early blood immunogenicity.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1835816","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:40:15Z","timestamp":1779169215000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond priming: a sequential, feedback-guided adjuvant framework for therapeutic cancer peptide vaccines in immunologically cold tumors"],"prefix":"10.3389","volume":"17","author":[{"given":"Corey K.","family":"Goldman","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, MedAlliance","place":["Bronx, NY, United States"]},{"name":"Leon H. Charney Division of Cardiology, Department of Medicine, NYU Grossman School of Medicine, NYU Langone Health","place":["New York, NY, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13111150","article-title":"Shaping antitumor immunity with peptide vaccines: implications of immune modulation at the vaccine site","volume":"13","author":"Sarkar","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12080950","article-title":"Advancements and challenges in peptide-based cancer vaccination: a multidisciplinary perspective","volume":"12","author":"Liu","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9749363","article-title":"Development of peptide-based vaccines for cancer","volume":"2022","author":"Abd-Aziz","year":"2022","journal-title":"J Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/cells12172159","article-title":"Cancer vaccine therapeutics: limitations and effectiveness-a literature review","volume":"12","author":"Kaczmarek","year":"2023","journal-title":"Cells"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coi.2016.11.001","article-title":"Peptide vaccines in cancer-old concept revisited","volume":"45","author":"Kumai","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-025-17281-1","article-title":"The landmark series: therapeutic cancer vaccine strategies for cold tumors","volume":"32","author":"Blair","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.6147","article-title":"In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer","volume":"27","author":"Pag\u00e8s","year":"2009","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1516","article-title":"Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides","volume":"18","author":"Filipazzi","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201142361","article-title":"Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8+ T-cell responses in melanoma patients","volume":"42","author":"Goldinger","year":"2012","journal-title":"Eur J Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.biocel.2014.04.019","article-title":"Cancer vaccines: trafficking of tumor-specific T cells to tumor after therapeutic vaccination","volume":"53","author":"Hailemichael","year":"2014","journal-title":"Int J Biochem Cell Biol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"7458","DOI":"10.1038\/ncomms8458","article-title":"Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints","volume":"6","author":"Mikucki","year":"2015","journal-title":"Nat Commun"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.11.007","article-title":"CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation \u2014 a target for novel cancer therapy","volume":"63","author":"Tokunaga","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2010.12.017","article-title":"CXCR3 in T cell function","volume":"317","author":"Groom","year":"2011","journal-title":"Exp Cell Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200108)31:8<2411::AID-IMMU2411>3.0.CO;2-Y","article-title":"A critical role for IL-12 in CCR5 induction on T cell receptor-triggered mouse CD4+ and CD8+ T cells","volume":"31","author":"Iwasaki","year":"2001","journal-title":"Eur J Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/126954","article-title":"CC chemokine receptor 5: the interface of host immunity and cancer","volume":"2014","author":"de Oliveira","year":"2014","journal-title":"Dis Markers"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.18.3836","article-title":"Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma","volume":"19","author":"Lee","year":"2001","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03144-1","article-title":"Interleukin-12 as an in situ cancer vaccine component: a review","volume":"71","author":"Cheng","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.952231","article-title":"IL12 immune therapy clinical trial review: novel strategies for avoiding CRS-associated cytokines","volume":"13","author":"Jia","year":"2022","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"B23","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutational burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e3181eacbc4","article-title":"Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer","volume":"16","author":"Fewkes","year":"2010","journal-title":"Cancer J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002903","article-title":"IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"9","author":"Pachynski","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1158\/1078-0432.CCR-24-1728","article-title":"A phase II open-label, randomized clinical trial of atezolizumab with or without human recombinant IL-7 (CYT107) in advanced urothelial cancer","volume":"31","author":"Sweis","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aag1266","article-title":"The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications","volume":"1","author":"Spiotto","year":"2016","journal-title":"Sci Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0994","article-title":"The abscopal effect of radiation therapy","volume":"17","author":"Craig","year":"2021","journal-title":"Future Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/med.22016","article-title":"cGAS-STING pathway agonists are promising vaccine adjuvants","volume":"44","author":"Tian","year":"2024","journal-title":"Med Res Rev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2024.1391046","article-title":"DNA sensing of dendritic cells in cancer immunotherapy","volume":"11","author":"Qian","year":"2024","journal-title":"Front Mol Biosci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2451","article-title":"A first-in-human phase I study of subcutaneous outpatient recombinant human IL15 (rhIL15) in adults with advanced solid tumors","volume":"24","author":"Miller","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0945","article-title":"Phase I trial of ALT-803, a novel recombinant IL15 complex, in patients with advanced solid tumors","volume":"24","author":"Margolin","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S1470-2045(18)30148-7","article-title":"ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial","volume":"19","author":"Wrangle","year":"2018","journal-title":"Lancet Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3944","article-title":"Intratumoral plasmid IL-12 expands CD8+ T cells and induces a CXCR3 gene signature in triple-negative breast tumors that sensitizes patients to anti-PD-1 therapy","volume":"27","author":"Telli","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.5193","article-title":"Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma","volume":"26","author":"Thompson","year":"2008","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0479-4","article-title":"IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma","volume":"57","author":"Frederiksen","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.0655","article-title":"Interleukin-21 has activity in patients with metastatic melanoma: a phase II study","volume":"30","author":"Petrella","year":"2012","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401236","article-title":"A context-dependent role for IL-21 in modulating the differentiation, distribution, and abundance of effector and memory CD8 T cell subsets","volume":"196","author":"Tian","year":"2016","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 superagonist NAI in BCG-unresponsive non-muscle-invasive bladder cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyag008","article-title":"The quadruple immunotherapy for colorectal cancer (QuICC) trial for mismatch repair-proficient metastatic colorectal cancer","volume":"31","author":"Bracken-Clarke","year":"2026","journal-title":"Oncologist"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1572","article-title":"A composite decision rule of CD8+ T-cell density in tumor biopsies predicts efficacy in early-stage immunotherapy trials","volume":"30","author":"Dejardin","year":"2024","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1835816\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T05:40:19Z","timestamp":1779169219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1835816\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2026.1835816"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1835816","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"article-number":"1835816"}}